nach oben

Die Ophthalmologie

Erschienen in:

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Ophthalmika in der Schwangerschaft

verfasst von: Prof. Dr. Torsten Schlote, Eric Chan, Ursula Germann

Erschienen in: Die Ophthalmologie | Ausgabe 4/2024

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden Übersicht wurden Literaturverzeichnisse (Pubmed Library), Arzneimittelverzeichnisse (Rote Liste, Schweizer Arzneimittelkompendium), Leitlinien von Fachgesellschaften (Deutsche Ophthalmologische Gesellschaft [DOG], Schweizerische Ophthalmologische Gesellschaft [SOG], European Glaucoma Society [EGS], American Academy of Ophthalmology [AAO]) und Internetportale (Embryotox, Reprotox) gesichtet und daraus Empfehlungen für den Einsatz von Ophthalmika in der Schwangerschaft und Stillzeit abgeleitet. Dem Thema sollte mehr Aufmerksamkeit in den Fachgesellschaften gewidmet werden.

Nur mit Berechtigung zugänglich

(2021) European glaucoma society terminology and guidelines for glaucoma, 5th edition. Br J Ophthalmol 105:1–169. https://doi.org/10.1136/bjophthalmol-2021-egsguidelines

Gotovac M, Kastelan S, Lukenda A (2013) Eye and pregnancy. Coll Antropol 37(1):189–193PubMed

Chawla S, Chaudhary T, Aggarwal S et al (2013) Ophthalmic considerations in pregnancy. Med J Armed Forces India 69:278. https://doi.org/10.1016/J.MJAFI.2013.03.006CrossRefPubMedPubMedCentral

NCBI Bookshelf Drugs and lactation database (LactMed®). https://www.ncbi.nlm.nih.gov/books/NBK501922/. Zugegriffen: 28. Febr. 2024

Wang X, Zhang Y, Yang H, Xu Y (2022) Maternal-fetal transfer of indocyanine green: a systematic review. J Matern Fetal Neonatal Med 35:8181–8185. https://doi.org/10.1080/14767058.2021.1966410CrossRefPubMed

Vaideanu D, Fraser S (2007) Glaucoma management in pregnancy: a questionnaire survey. Eye (Lond) 21:341–343. https://doi.org/10.1038/SJ.EYE.6702193CrossRefPubMed

Belkin A, Chen T, DeOliveria AR et al (2020) A practical guide to the pregnant and breastfeeding patient with glaucoma. Ophthalmol Glaucoma 3:79–89. https://doi.org/10.1016/J.OGLA.2019.12.004CrossRefPubMed

Gazzard G, Konstantakopoulou E, Garway-Heath D et al (2023) Laser in glaucoma and ocular hypertension (LiGHT) trial: six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology 130:139–151. https://doi.org/10.1016/J.OPHTHA.2022.09.009CrossRefPubMed

Výborný P, Sičáková S, Flórová Z, Sováková I (2017) Selective laser trabeculoplasty—implication for medicament glaucoma treatment interruption in pregnant and breastfeeding women. Cesk Slov Oftalmol 73:61–63PubMed

10.

Kaufman AR, Al-Djasim AL, Rivkin AC et al (2024) Pregnancy outcomes in the medical management of glaucoma: an international multicenter descriptive survey. Eur J Ophthalmol. https://doi.org/10.1177/11206721231199774CrossRefPubMed

11.

Vajaranant TS (2022) Clinical dilemma-topical prostaglandin use in glaucoma during pregnancy. JAMA Ophthalmol 140:637–638. https://doi.org/10.1001/JAMAOPHTHALMOL.2022.1092CrossRefPubMed

12.

Etminan M, Richter L, Sodhi M, Mikelberg FS (2022) Association of topical prostaglandin analogue use with risk of spontaneous abortion. JAMA Ophthalmol 140:634–636. https://doi.org/10.1001/JAMAOPHTHALMOL.2022.0628CrossRefPubMedPubMedCentral

13.

Kumari R, Saha BC, Onkar A et al (2021) Management of glaucoma in pregnancy—balancing safety with efficacy. Ther Adv Ophthalmol. https://doi.org/10.1177/25158414211022876CrossRefPubMedPubMedCentral

14.

Heikkilä AM (1993) Antibiotics in pregnancy—a prospective cohort study on the policy of antibiotic prescription. Ann Med 25:467–471. https://doi.org/10.3109/07853899309147314CrossRefPubMed

15.

Ness T, Paulus W (2012) Ophthalmic agents during pregnancy and breastfeeding. Ophthalmologe 109:221–228. https://doi.org/10.1007/s00347-011-2459-xCrossRefPubMed

16.

Giamarellou H, Kolokythas E, Petrikkos G et al (1989) Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med. https://doi.org/10.1016/0002-9343(89)90021-1CrossRefPubMed

17.

Rusu A, Munteanu AC, Arbănași EM, Uivarosi V (2023) Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile? Pharmaceutics. https://doi.org/10.3390/PHARMACEUTICS15030804/S1CrossRefPubMedPubMedCentral

18.

Lamont HF, Blogg HJ, Lamont RF (2014) Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. Expert Opin Drug Saf 13:1569–1581. https://doi.org/10.1517/14740338.2014.939580CrossRefPubMed

19.

Yefet E, Salim R, Chazan B et al (2014) The safety of quinolones in pregnancy. Obstet Gynecol Surv 69:681–694. https://doi.org/10.1097/OGX.0000000000000122CrossRefPubMed

20.

Reali A, Ximenes A, Cuzzolin L, Fanos V (2005) Antibiotic therapy in pregnancy and lactation. J Chemother 17:123–130. https://doi.org/10.1179/JOC.2005.17.2.123CrossRefPubMed

21.

Andersson NW, Olsen RH, Andersen JT (2021) Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ. https://doi.org/10.1136/BMJ.N107CrossRefPubMedPubMedCentral

22.

Samples JR, Meyer SM (1988) Use of ophthalmic medications in pregnant and nursing women. Am J Ophthalmol 106:616–623. https://doi.org/10.1016/0002-9394(88)90597-1CrossRefPubMed

23.

Drozhzhyna GI, Sereda EV, Gaydamaka TB, Molodaia AL (2017) Efficacy of using antibacterial fusidic acid drops in patients with red eye. Oftalmol Zh. https://doi.org/10.31288/OFTALMOLZH201713437CrossRef

24.

Thomseth V, Cejvanovic V, Jimenez-Solem E et al (2015) Exposure to topical chloramphenicol during pregnancy and the risk of congenital malformations: a Danish nationwide cohort study. Acta Ophthalmol 93:651–653. https://doi.org/10.1111/AOS.12737CrossRefPubMed

25.

Bookstaver PB, Bland CM, Griffin B et al (2015) A review of antibiotic use in pregnancy. Pharmacotherapy 35:1052–1062. https://doi.org/10.1002/PHAR.1649CrossRefPubMed

26.

Stone KM, Reiff-Eldridge R, White AD et al (2004) Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984–1999. Birth Defects Res Part A Clin Mol Teratol 70:201–207. https://doi.org/10.1002/BDRA.20013CrossRef

27.

Pasternak B, Hviid A (2010) Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 304:859–866. https://doi.org/10.1001/JAMA.2010.1206CrossRefPubMed

28.

Ward RM, Bates BA, Benitz WE et al (2001) Transfer of drugs and other chemicals into human milk. Pediatrics 108:776–789. https://doi.org/10.1542/PEDS.108.3.776CrossRef

29.

Miller BW, Howard TK, Goss JA et al (1995) Renal transplantation one week after conception. Transplantation 60:1353–1354PubMed

30.

Pescovitz MD (1999) Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient. Transplantation 67:758–759. https://doi.org/10.1097/00007890-199903150-00021CrossRefPubMed

31.

Sahay P, Singhal D, Nagpal R et al (2019) Pharmacologic therapy of mycotic keratitis. Surv Ophthalmol 64:380–400. https://doi.org/10.1016/J.SURVOPHTHAL.2019.02.007CrossRefPubMed

32.

Czeizel AE, Kazy Z, Vargha P (2003) A case-control teratological study of vaginal natamycin treatment during pregnancy. Reprod Toxicol 17:387–391. https://doi.org/10.1016/S0890-6238(03)00041-8CrossRefPubMed

33.

Cottreau JM, Barr VO (2016) A review of antiviral and antifungal use and safety during pregnancy. Pharmacotherapy 36:668–678. https://doi.org/10.1002/PHAR.1764CrossRefPubMed

34.

Sigera LSM, Denning DW (2023) Flucytosine and its clinical usage. Ther Adv Infect Dis. https://doi.org/10.1177/20499361231161387CrossRefPubMedPubMedCentral

35.

Murer T, Drr C, Brgler C et al (2020) Behandlung allergischer Erkrankungen in der Schwangerschaft. Swiss Med Forum. https://doi.org/10.4414/SMF.2020.08478CrossRef

36.

Hansen C, Desrosiers TA, Wisniewski K et al (2020) Use of antihistamine medications during early pregnancy and selected birth defects: the national birth defects prevention study, 1997–2011. Birth Defects Res 112:1234–1252. https://doi.org/10.1002/BDR2.1749CrossRefPubMedPubMedCentral

37.

Kar S, Krishnan A, Preetha K, Mohankar A (2012) A review of antihistamines used during pregnancy. J Pharmacol Pharmacother 3:105. https://doi.org/10.4103/0976-500X.95503CrossRefPubMedPubMedCentral

38.

Etwel F, Faught LH, Rieder MJ, Koren G (2017) The risk of adverse pregnancy outcome after first trimester exposure to H1 antihistamines: a systematic review and meta-analysis. Drug Saf 40:121–132. https://doi.org/10.1007/S40264-016-0479-9CrossRefPubMed

39.

Gilboa SM, Ailes EC, Rai RP et al (2014) Antihistamines and birth defects: a systematic review of the literature. Expert Opin Drug Saf 13:1667–1698. https://doi.org/10.1517/14740338.2014.970164CrossRefPubMedPubMedCentral

40.

Almawi WY, Saldanha FL, Mahmood NA et al (2013) Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage. Hum Reprod 28:2628–2635. https://doi.org/10.1093/HUMREP/DET308CrossRefPubMed

41.

Avery RL, Castellarin AA, Steinle NC et al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98:1636–1641. https://doi.org/10.1136/BJOPHTHALMOL-2014-305252CrossRefPubMed

42.

Sakai T, Mori C, Ohtsu F (2022) Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: a disproportionality analysis using the food and drug administration adverse event reporting system. Front Pharmacol. https://doi.org/10.3389/FPHAR.2022.1063625CrossRefPubMedPubMedCentral

43.

Ong AY, Kiire CA, Frise C et al (2023) Intravitreal anti-vascular endothelial growth factor injections in pregnancy and breastfeeding: a case series and systematic review of the literature. Eye (Lond) 2023:1–13. https://doi.org/10.1038/s41433-023-02811-6CrossRef

44.

Vuorela P, Andersson S, Carpen O et al (2000) Unbound vascular endothelial growth factor and its receptors in breast, human milk, and newborn intestine. Am J Clin Nutr 72:1196–1201. https://doi.org/10.1093/AJCN/72.5.1196CrossRefPubMed

45.

Juncal VR, Paracha Q, Bamakrid M et al (2020) Ranibizumab and aflibercept levels in breast milk after intravitreal injection. Ophthalmology 127:278–280. https://doi.org/10.1016/J.OPHTHA.2019.08.022CrossRefPubMed

46.

Marlow N, Stahl A, Lepore D et al (2021) 2‑year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health 5:698–707. https://doi.org/10.1016/S2352-4642(21)00195-4CrossRefPubMed

Titel: Ophthalmika in der Schwangerschaft
verfasst von: Prof. Dr. Torsten Schlote
Eric Chan
Ursula Germann
Publikationsdatum: 08.04.2024
Verlag: Springer Medizin
Schlagwörter: Therapieverfahren in der Augenheilkunde
Medikamente in Schwangerschaft und Stillzeit
Erytheme
Glaukom
Tropicamid
ß-Sympathomimetika
Brimonidin
Timolol
Antibiotika
Lokale Antimykotika
Atropin
Erschienen in: Die Ophthalmologie / Ausgabe 4/2024
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-024-02025-5

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Ophthalmika in der Schwangerschaft

Zusammenfassung

Neu im Fachgebiet Augenheilkunde